Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Neoplasm of Uncertain Histogenesis — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Special Category
Neoplasm of Uncertain Histogenesis

Cancer

Neoplasm of Uncertain Histogenesis

CI-CAN-00000034Explore in graph →

Non-malignant20,280 active trials259 approved drugs3,813 evidence items

NCIt: C6974
OncoTree: MBT
UMLS CUI: C1334936

Overview
Statistics
Survival
Genomics465
Variants & evidence3813
Drugs427
Trials91351
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (4,399)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 3,876–3,900 of 4,399 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Neuregulin 1 expression is a predictive biomarker for response to AV-203, an ERBB3 inhibitory antibody, in human tumor models.
· Clin Cancer Res · 2015 · PMID 25542901 · validated civic_curation pubmed
HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models.
· Oncotarget · 2014 · PMID 25216528 · validated civic_curation pubmed
UDP glucuronosyltransferase 1A expression levels determine the response of colorectal cancer cells to the heat shock protein 90 inhibitor ganetespib.
· Cell Death Dis · 2014 · PMID 25210794 · validated civic_curation pubmed
Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells.
· Cell Cycle · 2015 · PMID 25590338 · validated civic_curation pubmed
Loss of NAPRT1 expression by tumor-specific promoter methylation provides a novel predictive biomarker for NAMPT inhibitors.
· Clin Cancer Res · 2013 · PMID 24097869 · validated civic_curation pubmed
The EMT activator ZEB1 promotes tumor growth and determines differential response to chemotherapy in mantle cell lymphoma.
· Cell Death Differ · 2014 · PMID 24013721 · validated civic_curation pubmed
Metastasis-associated PRL-3 induces EGFR activation and addiction in cancer cells.
· J Clin Invest · 2013 · PMID 23867504 · validated

Showing 3,876–3,900 of 4,399 publications

← Previous
1
…
155
156
157
…
176
Next →

civic_curation

Elevation of c-FLIP in castrate-resistant prostate cancer antagonizes therapeutic response to androgen receptor-targeted therapy.

· Clin Cancer Res · 2012 · PMID 22623731 · validated civic_curation pubmed

Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.

· Oncogene · 2011 · PMID 20956938 · validated civic_curation pubmed

Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer.

· Cancer Res · 2008 · PMID 18593940 · validated civic_curation pubmed

MRP7/ABCC10 expression is a predictive biomarker for the resistance to paclitaxel in non-small cell lung cancer.

· Mol Cancer Ther · 2008 · PMID 18445659 · validated civic_curation pubmed

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.

· Cancer Discov · 2014 · PMID 24893891 · validated civic_curation pubmed

Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma.

· PLoS One · 2016 · PMID 26821351 · validated civic_curation pubmed

Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.

· J Clin Invest · 2011 · PMID 21985784 · validated civic_curation pubmed

Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells.

· Oncogene · 2005 · PMID 16091755 · validated civic_curation pubmed

Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.

· Nat Med · 2013 · PMID 24162815 · validated civic_curation pubmed

Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.

· Nat Med · 2006 · PMID 16341243 · validated civic_curation pubmed

Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.

· Blood · 2013 · PMID 23430109 · validated civic_curation pubmed

FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro.

· Cancer Res · 2009 · PMID 19318574 · validated civic_curation pubmed

Hedgehog pathway inhibitor saridegib (IPI-926) increases lifespan in a mouse medulloblastoma model.

· Proc Natl Acad Sci U S A · 2012 · PMID 22550175 · validated civic_curation pubmed

Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.

· Clin Cancer Res · 2015 · PMID 25351743 · validated civic_curation pubmed

Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia.

· Nat Chem Biol · 2015 · PMID 26167872 · validated civic_curation pubmed

FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer.

· Cancer Res · 2010 · PMID 20179196 · validated civic_curation pubmed

KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors.

· Cancer Res · 2009 · PMID 19723655 · validated civic_curation pubmed

Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.

· Nature · 2013 · PMID 23934108 · validated civic_curation pubmed